By Sheeba M. | Weedstock Market Intelligence | October 29, 2026 — 2:00 PM ET
The cannabis regulatory landscape rarely sits still, and October 29, 2026 is no exception. From the federal scheduling pipeline to state-level adult-use buildouts, the policy environment continues to evolve in ways that will directly shape which operators win, which states emerge as growth markets, and whether the structural headwinds that have suppressed cannabis valuations finally begin to lift. Here is the current regulatory picture as of today’s session.
Federal Front: DEA Scheduling Review Remains the North Star
The DEA’s ongoing review of cannabis’s Schedule I classification remains the dominant federal catalyst in the sector’s thesis. While no final ruling has been issued, the administrative process continues to move — slowly, as regulators balance public comment records, HHS recommendations, and legal challenge risk. Market participants are watching for any signal that the review timeline is accelerating or, conversely, facing political headwinds that could push resolution further into 2027.
The practical implications of a Schedule III reclassification would be significant, particularly around 280E tax relief. Under current law, cannabis businesses cannot deduct ordinary business expenses because they traffic in a Schedule I controlled substance — a structural disadvantage that artificially suppresses profitability and distorts the financial comparisons investors use to evaluate these companies. Rescheduling to Schedule III would eliminate 280E’s applicability and, overnight, make many cannabis operators dramatically more financially attractive on a GAAP basis.
It is worth noting that rescheduling would not federally legalize cannabis — it would remain a controlled substance, just in a different category. Full federal legalization would require Congressional action, which remains unlikely in the near-term given the current legislative calendar and political dynamics. Nevertheless, the scheduling question is the single most important federal variable for cannabis investors right now, and any movement — positive or negative — will reprice the sector quickly. Keep the cannabis tracker bookmarked for rapid response to any federal headlines.
SAFER Banking Act: Still in the Queue
The SAFER Banking Act — which would provide cannabis businesses with access to federally insured banking services and remove the compliance risks that have kept most major financial institutions away from the sector — remains active in Congress but has not advanced to a floor vote as of this writing. The bill has bipartisan support in the Senate, and banking industry lobbying behind it has grown. However, House dynamics and the broader legislative calendar have repeatedly delayed action.
For operators, continued lack of SAFER passage means ongoing reliance on state-chartered banks, credit unions, and cash-heavy operations — all of which add cost and operational complexity. For investors, it means the sector continues to trade at a discount to what normalized banking access would imply. The passage of SAFER would not be as explosive a catalyst as rescheduling, but it would be a meaningful structural improvement that sophisticated investors would price positively.
State-Level Developments: Pennsylvania, Ohio, and the Midwest Buildout
Pennsylvania continues its adult-use licensing process following last year’s legalization vote. The regulatory framework is taking shape, and operators with existing medical licenses in the state — including Trulieve, GTI, Curaleaf, and Cresco Labs — are positioned to convert and expand. Pennsylvania is one of the largest remaining adult-use market unlocks in the Northeast, and its full activation will meaningfully add to revenue for the MSOs with heavy in-state exposure. Analysts are watching the license conversion timeline carefully; delays are possible given the complexity of the rulemaking process.
Ohio adult-use conversion, which launched in 2025, continues to mature. Early data from the Buckeye State suggests the market is developing ahead of some projections, particularly in suburban and mid-size city dispensary locations. Green Thumb and Verano both have significant Ohio exposure and have referenced the state positively in recent earnings commentary. As Ohio competes with Michigan — the Midwest’s established adult-use leader — operational execution at the dispensary level will determine which operators capture disproportionate share.
Florida remains the wildcard. Adult-use legalization via ballot initiative failed in 2024, and the political landscape for another attempt is being assessed by advocacy groups. Florida’s existing medical market is the largest in the country by revenue, and its eventual adult-use transition — whenever it comes — will be the single largest market unlock remaining in the U.S. Curaleaf and Trulieve, both of which built dominant Florida positions under the medical framework, stand to be the biggest beneficiaries when that transition finally happens.
International Picture: Germany and European Medical Momentum
Germany’s medical cannabis market continues to expand following its 2024 regulatory overhaul, providing a meaningful revenue stream for Canadian LPs with export capabilities. Aurora Cannabis, Tilray, and OrganiGram are among the LPs benefiting from European medical demand. The German adult-use framework remains in pilot stages, and the political willingness to expand it will be a key variable for LP export revenue growth in 2027 and beyond.
Investors following the international angle should also watch for any developments in the UK, where medical cannabis prescription volumes are growing from a low base, and in Australia, where adult-use discussions are beginning to emerge at the federal level. These are longer-dated catalysts, but they are part of the global market development story that underpins the LP investment thesis.
The regulatory environment for cannabis in 2026 is complex, layered, and deeply consequential for equity valuations. Staying current on policy developments — federal and state — is essential for anyone actively managing positions in this sector. Use the Weedstock cannabis equity tracker alongside this regulatory context to build a complete picture of where the risk and opportunity lie today.
Sheeba M. covers cannabis equities and market intelligence for Weedstock. This content is for informational purposes only and does not constitute investment advice.